Latest Stocks: Sophiris Bio Inc (SPHS) PT Set at $6.00 by Maxim Group

Sophiris Bio Inc (NASDAQ:SPHS) has been assigned a $6.00 price objective by investment analysts at Maxim Group in a report issued on Tuesday, May 16th. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Maxim Group’s price target suggests a potential upside of 144.90% from the company’s current price.

SPHS has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Sophiris Bio in a research report on Tuesday, March 28th. Rodman & Renshaw restated a “buy” rating and set a $6.00 price target on shares of Sophiris Bio in a research note on Tuesday, March 28th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $7.00 price target on shares of Sophiris Bio in a research note on Thursday, April 6th. Six analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $6.33.

Sophiris Bio (SPHS) opened at 2.45 on Tuesday. Sophiris Bio has a 52 week low of $0.98 and a 52 week high of $8.55. The stock’s 50 day moving average price is $2.53 and its 200 day moving average price is $2.70. The firm’s market capitalization is $73.77 million.

Sophiris Bio (NASDAQ:SPHS) last released its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.09). On average, equities analysts expect that Sophiris Bio will post ($0.39) EPS for the current year. An institutional investor recently bought a new position in Sophiris Bio stock. Oxford Asset Management purchased a new stake in shares of Sophiris Bio Inc (NASDAQ:SPHS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 175,198 shares of the biopharmaceutical company’s stock, valued at approximately $491,000. Oxford Asset Management owned 0.58% of Sophiris Bio at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.99% of the company’s stock.